Paper Details

  1. Home
  2. Paper Details

Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma.

Author: Ben-ShushanDikla, BlauRachel, Eldar-BoockAnat, EpshteinYana, FridrichLidar, Koshrovski-MichaelShani, KrivitskyAdva, PisarevskyEvgeni, PozziSabina, Satchi-FainaroRonit, ScomparinAnna, Shenbach-KoltinGal, TiramGalia, WhiteRichard, YeiniEilam

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study develops a novel nanomedicine delivery system using poly(α,L-glutamic acid) (PGA) to target melanoma tumors with a combination of selumetinib (SLM) and modified dabrafenib (mDBF), both targeting the RAS/RAF/MEK/ERK pathway. The study demonstrates that the nanomedicine exhibits synergistic anti-tumor activity in vitro and in a mouse model of primary melanoma, suggesting a promising approach for cancer treatment.
Paper Details　
Original Abstract of the Article :
Targeted therapies against cancer can relieve symptoms and induce remission, however, they often present limited duration of disease control, cause side effects and often induce acquired resistance. Therefore, there is a great motivation to develop a unique delivery system, targeted to the tumor, in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35754977

データ提供：米国国立医学図書館（NLM）

Fighting Melanoma: A Camel's Journey Through Targeted Therapy

This research is like a skilled desert navigator, seeking to pinpoint and target the source of a deadly sandstorm. The study focuses on melanoma, a type of skin cancer, and explores a novel nanomedicine approach to deliver a combination of drugs that specifically target the mutated BRAF and MEK pathways involved in cancer growth.

A New Weapon Against Melanoma: Nanomedicine Offers Hope

The study demonstrates that the nanomedicine, composed of polyglutamic acid conjugated with selumetinib and modified dabrafenib, effectively inhibited melanoma cell proliferation and reduced their invasive potential. This innovative approach offers a promising new avenue for treating melanoma, potentially improving treatment outcomes and prolonging patient survival.

A Camel's Perspective on Cancer Treatment

Melanoma is a serious threat, like a relentless desert sandstorm. This research represents a significant step forward in the fight against this disease. The development of targeted therapies and innovative delivery systems is a testament to the dedication of researchers to find effective solutions for cancer.

Dr. Camel's Conclusion

This research is a shining beacon of hope in the desert of cancer treatment. The use of nanomedicine to deliver a combination of targeted drugs offers a promising new approach to fighting melanoma. It's a reminder that innovation and collaboration are essential in the pursuit of better treatments for cancer and a brighter future for patients.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35754977

DOI: Digital Object Identifier

NIHMS1789389

Related Literature

Article Analysis
・Side Effects of selumetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.